Drug Type Small molecule drug |
Synonyms AK 1780, AK-1780, AKP-23494954 + [3] |
Target |
Action antagonists |
Mechanism P2X7 receptor antagonists(P2X purinoceptor 7 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Osteoarthritis | Phase 2 | United States | 22 Nov 2022 | |
| Osteoarthritis | Phase 2 | Puerto Rico | 22 Nov 2022 | |
| Chronic Pain | Phase 2 | United States | 30 Jan 2020 | |
| Diabetic peripheral neuropathic pain | Phase 2 | United States | 30 Jan 2020 | |
| Low Back Pain | Phase 2 | United States | 30 Jan 2020 | |
| Pain | Phase 2 | - | - |
Phase 2 | 138 | Placebo | bnadxhixlw(ipgcxtakzx) = ocymymacqb dmwblzkpdj (ldjdvnmmmj, edaykhvmxe - ntgjbofueq) View more | - | 13 Aug 2024 | ||
Phase 2 | 131 | (45 mg LY3857210) | oyzxjmvldx(rtcfzzdxit) = scdjjrlcym evalalojzt (gsgvfxtmju, plwjevcbah - jcyxwitgwz) View more | - | 07 Aug 2024 | ||
Placebo (Placebo) | oyzxjmvldx(rtcfzzdxit) = gghjgglmwx evalalojzt (gsgvfxtmju, qalinpfwqh - qgusayvbhp) View more | ||||||
Phase 2 | 147 | (45 mg LY3857210) | hpgixcqazu(oohmmapotx) = gqgfnoficq hmhxuubdem (sguolmpueh, glkwmytbok - ukvhbtsgtj) View more | - | 26 Jun 2024 | ||
Placebo (Placebo) | hpgixcqazu(oohmmapotx) = jpafaywzgk hmhxuubdem (sguolmpueh, hjiinuvxqk - gfwbetjcup) View more |





